Acumen Pharmaceuticals, Inc. Current Assets
Acumen Pharmaceuticals, Inc. (ABOS) had Current Assets of $115.51 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-12
- 2026-06-30: Assets, Current $115.51M.
- 2026-03-31: Assets, Current $133.09M.
- 2025-12-31: Assets, Current $122.25M.
- 2025-09-30: Assets, Current $132.15M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $115.51M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $133.09M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $122.25M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $132.15M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $148.40M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $154.95M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $178.31M 10-K · filed 2026-03-26 |
| 2024-09-30 | $207.63M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $266.92M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $255.83M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $246.62M 10-K · filed 2025-03-27 |
| 2023-09-30 | $218.60M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $149.54M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $144.03M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $180.33M 10-K · filed 2024-03-26 |
| 2022-09-30 | $202.56M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $191.05M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $192.10M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $198.66M 10-K · filed 2023-03-27 |
| 2021-09-30 | $204.91M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $70.57M 10-Q · filed 2021-08-16 |
| 2020-12-31 | $44.43M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |